RecruitingPhase 3

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

United States110 participantsStarted 2022-11-09

Plain-language summary

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Patients 18-80 years of age with a diagnosis of a hematological malignancy * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies Exclusion Criteria: * • Patients enrolled in investigational clinical trials * Sct for non hematologic malignancies

What they're measuring

non-infectious fever

Timeframe: 30 days post stem cell transplant

Trial details

NCT IDNCT05509933

SponsorHenry Ford Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-30

Contact for this trial

shatha farhan

3137133910 sfarhan1@hfhs.org

View on ClinicalTrials.gov More Engraftment Syndrome trials